Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on X:
“Oncology dealmaking dropped 50% in 2024 (~$90B), but cancer remains the top category.
Trends shaping the future:
- Shift from niche biomarker drugs to pan-cancer strategies
- Surge in ADCs, RLTs and bi/trispecifics
The race for next-gen precision plus scale is on!”
More posts featuring Aakash Desai .
